Christina M. Ohnsman, MD
Chief Medical Officer
Dr. Christina Ohnsman is Co-CEO and Chief Medical Officer of Tern Therapeutics. Prior to cofounding Tern, Dr. Ohnsman was Executive Director of Clinical Development at REGENXBIO Inc., where she led global clinical development for rare ocular and CNS diseases, including CLN2 Batten disease, and provided strategic clinical guidance for early discovery and preclinical research, portfolio planning, and business development. A serial entrepreneur, as the founder of a biopharma communications and consulting firm, Dr. Ohnsman previously provided strategic guidance in clinical development, medical affairs, business development, commercialization, post-marketing development, and health economics and outcomes for life sciences clients, including Spark Therapeutics, Inc. She began her career as the founder of a solo pediatric ophthalmology practice while serving on the faculty of Wills Eye Hospital in Philadelphia. Dr. Ohnsman received her MD from UMDNJ-New Jersey Medical School.
123-456-7890